Interpace announces Q3 2026 earnings with $10.4M revenue and adjusted EBITDA expansion
Interpace Biosciences reported third quarter revenue of $10.4 million and an 18% year-over-year increase in Adjusted EBITDA, driven by growth in its thyroid business. The company remains focused on laboratory automation and R&D investments following the discontinuation of its PancraGEN business.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed